Raxtozinameran

Approval Year

Substance Class	Nucleic Acid Created by `admin` on `Sat Dec 16 19:51:57 GMT 2023` Edited by `admin` on `Sat Dec 16 19:51:57 GMT 2023`
Nucleic Acid Type	mRNA VACCINE
Nucleic Acid Subtype	VIRAL ENVELOPE PROTEIN
Sequence Origin	VIRAL
Sequence Type	COMPLETE
Record UNII	N36VHK46PR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Raxtozinameran

Official Name

English

BNT162b2 Omicron (XBB.1.5)

Preferred Name

English

RNA (recombinant 5′-[1,2-[(3′-O-methyl)m7G-(5′→5′)-ppp-Am]]-capped all uridine→N1-methylpseudouridine-substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptide plus codon-optimized pre-fusion spik

Common Name

English

RBP-020.2 4 (XBB.1.5 variant)

Common Name

English

messenger RNA (mRNA), 5'-capped, encoding a full-length, codon-optimised pre-fusion stabilised conformation variant (K982P and V983P) of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike (S) glycoprotein (Omicron sub-lineage XBB.1.5;

Common Name

English

raxtozinameran [INN]

Common Name

English

Code System Code Type Description

INN

13075

Created by admin on Sat Dec 16 19:51:57 GMT 2023 , Edited by admin on Sat Dec 16 19:51:57 GMT 2023

PRIMARY

CAS

2887554-49-4

Created by admin on Sat Dec 16 19:51:57 GMT 2023 , Edited by admin on Sat Dec 16 19:51:57 GMT 2023

PRIMARY

FDA UNII

N36VHK46PR

Created by admin on Sat Dec 16 19:51:57 GMT 2023 , Edited by admin on Sat Dec 16 19:51:57 GMT 2023

PRIMARY

Sugar	Site Range	Site Count
D-Ribose (RNA)	1_1-1_4271	4271 / 4271

Linkage	Site Range	Site Count
Phosphate	1_2-1_4271	4270 / 4270

Related Record Type Details


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->VACCINE ANTIGEN

Amount:

Related Record Type Details


					N36VHK46PR

Raxtozinameran

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
NUCLEOSIDE_SUBSTITUTION			U		N1-METHYLPSEUDOURIDINE	09RAD4M6WF
NUCLEOTIDE SUBSTITUTION					m2-7,3’-OGppp(m1-2’-O)Ap mRNA CAP	VNP8CZY34V